RNS Number:1959R
Provalis PLC
13 September 2005


Provalis plc

Notice of results

Provalis plc (LSE: PRO), the international medical diagnostics and
pharmaceuticals group, will be announcing preliminary results for the year ended
30 June 2005 on Wednesday, 19 October 2005.


                                                               13 September 2005


For further details please contact:

College Hill                                                       020 7457 2020
Corinna Dorward/ Adrian Duffield


Provalis plc (LSE: PRO) (http://www.provalis.com) is an international healthcare
group with two operating businesses:-
     
*    Medical Diagnostics - The business' principal products are in2it TMA1c and 
     Glycosal(R), both diabetes diagnostic tests.  In2itTMA1c is a fully
     automated, point of care, diabetes diagnostic, testing platform which has
     marketing clearance from the FDA in the US for use in both physicians' 
     offices and at home on prescription.

*    Pharmaceuticals - sells and markets its own, and third party, branded, 
     prescription medicines in the UK and Ireland to GPs and hospitals through 
     its regionally managed sales force. The business' principal product is
     Diclomax(R), a medicine for use in the treatment of musculo-skeletal 
     disorders, and it also sells products in the areas of osteoporosis, 
     migraine and dermatology.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of
1995: Statements in this announcement that relate to future plans, expectations,
events, performances and the like are forward-looking statements as defined in
the US Private Securities Litigation Reform Act of 1995. Actual results of
events could differ materially from those described in the forward-looking
statements due to a variety of factors.  Such factors include, among others: the
viability of the Group's products, which are at various stages of development;
the generation of sufficient operating cash flow by the Group's pharmaceutical
and medical diagnostic businesses to finance the ongoing development of these
businesses as well as the Group's research and development activities; the
success of the Group's research and development strategy and activities;
uncertainties related to future clinical trial results and the associated
regulatory process; the execution and success of collaborative agreements with
third parties; availability and level of reimbursement for the Group's products
from government health administration authorities or other third-party payors;
the rate of net cash utilisation within the Group and, hence, the Group's
possible need for additional capital in the short, medium and/or long term; the
Group's intellectual property position and the success of patent applications
for its products and technologies; the Group's dependence on key personnel;
general business and economic conditions; the impact of future laws, regulations
and policies; stock market trends in the Group's sector; and other factors
beyond the Group's control that may cause the Group's available capital
resources to be used more quickly than expected.  These and other factors that
could affect the Company's future results are more fully described in its
filings with the US Securities and


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NOREAFNDFASSEFE
Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024 Plus de graphiques de la Bourse Globaldata
Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Globaldata